Results of a Phase I trial of OMP-54F28 (FZD8-Fc), an investigational drug candidate discovered by OncoMed Pharmaceuticals targeting cancer stem cells (CSCs), were reported by University of Colorado Cancer Center researchers at the 50th Annual Meeting of the American Society for Clinical Oncology (ASCO). The drug was generally well tolerated, and several of the 26 patients with advanced solid tumors experienced stable disease for greater than six months. Three trials ...
Read More
No comments:
Post a Comment